A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies

Inclusion Criteria: * Ability of participant to understand this study, and participant to sign a written informed consent. Legally authorized representative is not allowed to sign consent for participant. * Participants with tumor protein 53 (TP53) immunohistochemistry (IHC)-positive tumors * Participants whose screening IHC shows TP53-IHC-negative including wild type (WT) and null. * Participants with histologic or cytologic confirmation of any malignant disease who are planning and eligible to undergo surgical resection. For participants with Solid Tumors Only * Participants with previously treated acute myeloid leukemia (AML) are eligible if they relapse and are in between two treatment regimens * No concurrent or recent (within 30 days) use of systemic therapy including chemotherapy, immunotherapy, hormonal therapy, cancer vaccine, or local therapy for the cancer. * Formalin-fixed paraffin-embedded (FFPE) tumor tissue deemed adequate for IHC analysis and next generation sequencing (NGS) are required. Bone marrow aspirate tissue samples from participants with AML are required. * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 * Adequate organ and marrow function * A negative urine or serum pregnancy test within 7 days before Day 1 dose of study medication, if female participant is of childbearing potential. * Women of child-bearing potential and men with partners of child-bearing potential must agree to practice sexual abstinence, or to use two form…